NCI
Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients
Patients will be randomized to receive various chemotherapy regimens depending on how Signatera identifies their minimal residual disease status.
Lung Cancers in Non-Smokers Fall Into Informative Molecular Subtypes
Whole-genome sequencing of lung cancers in never smokers highlighted three copy number-based subtypes, along with alterations linked to patient outcomes.
Blood Testing Distinguishes Benign Tumors From Precancerous Condition
Researchers used ultra-low-pass whole genome sequencing and cell-free DNA fragment size selection to detect pre-cancer in neurofibromatosis type 1 patients.
Long-term NCI Follow-up of TIL Therapy for Melanoma Sheds Light on Potential Frontline Benefit
Researchers evaluated metastatic melanoma patients treated with autologous TILs over two decades and found that prior treatment impacted survival benefit.
Geisinger Health System Wins $3.6M NIH Grant to Study Genetics of Cancer Risk
The health system will partner with the NCI to look for new cancer risk variants in a large population biobank, in the hopes of improving screening and care.